BSE See NSE See 38,040.57
15.12 (0.04%)
A Mixed Bag

A Mixed Bag


While the world is moving towards easing the lockdowns, the new wave of infections and the failure of the economic stimulus package in India to bring about any cheer have continued to keep the markets on the edge.

To read the entire article, you must be a DSIJ magazine subscriber.


Comments are only visible to subscribers.

DSIJ Mindshare

Glenmark to launch higher strength version of oral antiviral FabiFlu

Anthony Fernandes / Article rating: 4.7

Global pharma major, Glenmark Pharmaceuticals announced on Thursday that it is launching a 400 mg version of oral antiviral FabiFlu, for the treatment of mild to moderate COVID-19 in India. Glenmark Pharmaceuticals was the first company in the country to have received the regulator’s approval for 400 mg dosage form.